NCT02899052 : A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaMultiple Myeloma

Trial Overview Read MoreRead more

This trial aims to evaluate the safety and effectiveness of a targeted cancer therapy in combination with a type of chemotherapy in multiple myeloma patients that have got worse or not responded to at least one prior treatment.
 

This trial is treating patients with multiple myeloma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Commercial Sponsor

AbbVie

Summary

Evaluation will occur in four parts, with Part 1 being used to determine the appropriate doses of venetoclax and carfilzomib to use in later parts of the trial. Until appropriate doses have been confirmed, eligible participants will receive Venetoclax at a dose of 400 mg or 800 mg; Carfilzomib at a dose of 20/27 mg/m2, 20/70 mg/m2, and/or 20/56 mg/m2; and Dexamethasone at a 40 mg dose. Parts 2-4 will further evaluate the safety and efficacy of the treatment combination.

Recruiting Hospitals Read MoreRead more

Border Medical Oncology
Albury
Ms Nyree Sarakis
Nsarkis@bordermedonc.com.au
02 6064 1493

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next